Related coverage linked through entity extraction aliases.
Feb 24, 2026
AI systems are evolving into essential research collaborators in 2026, while quantum computing emerges as a transformative technology with potential to create $200-500 billion in value for life sciences by 2035.
Feb 24, 2026
The FDA reversed its decision to reject Moderna's mRNA influenza vaccine application, accepting it for review one week after an initial refusal-to-file that reportedly involved senior leaders overruling staff advice.
Feb 14, 2026
Multiple institutional investors expanded their positions in AstraZeneca during the third quarter, with AMG National Trust Bank, Cibc World Market Inc., and Advisors Asset Management Inc. increasing holdings by approximately 20%.
Feb 20, 2026
Scientists in Shanghai have developed DeepRare, an AI system that diagnoses rare diseases with 79% accuracy, outperforming experienced doctors in head-to-head testing. The system is now being used by clinicians at over 600 institutions worldwide.
Feb 16, 2026
The drug development services market is projected to reach $31.5 billion in 2026, growing at 12.2% CAGR, while AI-designed drugs enter pivotal Phase III trials that will determine whether the technology can improve clinical success rates beyond the industry's persistent 90% failure rate.
Feb 19, 2026
DeepRare, a multi-agent AI system, demonstrated exceptional performance in diagnosing rare diseases across 2,919 conditions, achieving 70.6% accuracy with genomic data and outperforming existing clinical tools in international testing.
Feb 18, 2026
The FDA agreed to review Moderna's mRNA flu vaccine after initially refusing the application, while separately announcing it will drop its longtime requirement for two clinical studies to approve new drugs.
Feb 18, 2026
The U.S. orphan drug market is projected to exceed $200 billion by 2031, driven by innovation in oncology and genetic disorders. More than 1,400 FDA-designated orphan drugs are in development or marketed, with over 800 currently in clinical trials.
Feb 12, 2026
The mRNA therapy market is forecast to grow from USD 13.6 billion in 2025 to USD 70.0 billion by 2035 at a 17.8% CAGR, driven by expanding applications beyond vaccines into oncology, rare diseases, and infectious disease treatments including genital herpes.
